Rheumatoid Arthritis
JAK inhibitors: A risk assessment
Coal mining, silica dust associated with rheumatoid arthritis in Appalachia
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
Risankizumab effective against refractory psoriatic arthritis
Cycling JAK inhibitors shows similar effectiveness to switching to a bDMARD in difficult-to-treat RA
Pre-existing heart failure affects safety of hydroxychloroquine in RA patients
Patients with RA-associated interstitial lung disease benefit from antifibrotic agent
Ultra-low dosing of rituximab in RA is a viable treatment option
Kidney disease and hydroxychloroquine dose are risk factors for developing retinopathy
More pros than cons for the use of statins in RA
Vaccinated rheumatic patients carry increased risk for COVID-19 breakthrough infections
B-cell depleting medication increases COVID-19 breakthrough infection outcome risk
COVID-19 mRNA vaccine safe and tolerable in adults with autoimmune disease
Two-dose COVID-19 vaccination may not lead to flares in RA patients
Support for TNF-inhibitor monotherapy in COVID patients with RA and related diseases
B-cell-targeted therapy linked with severe COVID-19 among patients with arthritis
Pausing mycophenolate boosts COVID-19-vaccine response in patients with rheumatic and musculoskeletal diseases
Live varicella-zoster vaccine safe, effective with TNF inhibitors
Could steroid treatment speed recovery from infliximab-induced liver injury?
Severe flares of rheumatic, musculoskeletal disease rare after COVID-19 vaccination
Does passive smoking exposure in childhood increase adult rheumatoid arthritis risk?
New target to dial down inflammation and pain discovered
JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
Rituximab or JAK inhibitors increase the risk of severe COVID-19
Remote management of RA is a feasible alternative for outpatient follow-up
Passive smoking associated with an increased risk of RA
TOVERA: Ultrasound is a promising biomarker of early treatment response
The risks of polypharmacy in RA
ABBV-3373: A potential new therapeutic agent for RA
JAK inhibitors and bDMARDs show comparable effectiveness
Vector-based vaccines likely more effective in patients on rituximab
Timely second COVID shot especially important for rheumatoid arthritis patients
Patients with rheumatic disease may experience flares after SARS-CoV-2 vaccination
Starting methotrexate, bridging glucocorticoids effective in early, high-risk RA
Non-invasive vagus nerve stimulation tolerated, effective for rheumatoid arthritis
Modern treatment tied to low disease activity in pregnant rheumatoid arthritis patients
COVID outcomes have improved over time in patients with rheumatic disease
Persuasive long-term results for JAK inhibition in rheumatoid arthritis
Rheumatoid arthritis: new EULAR treatment guidelines
Rheumatoid arthritis and interstitial lung disease: a deadly combination
COVID-19 in patients with rheumatic disease: most report mild disease
Poor disease control: a risk factor for severe COVID-19
No heightened outcome risk for rheumatic patients with COVID-19
Hydroxychloroquine use: no indication for arrhythmias in RA and SLE patients
Insufficient antimalarial supply for rheumatic disease treatment in the early COVID-19 pandemic
Patients with RA have higher risk of developing diabetes
Activated B cells could hold key to early-stage autoimmunity in rheumatoid arthritis
Switch between JAK and TNF inhibitors safe, effective for rheumatoid arthritis
Upadacitinib safety similar to other JAK inhibitors for rheumatoid arthritis
Upadacitinib superior to abatacept for arthritis but sparks more side effects
Low-dose glucocorticoids for rheumatoid arthritis may still carry some risk of serious infections
New nanoparticle promising future agent in RA
Olokizumab significantly improves RA features and patient-reported outcomes
Low DAS at 4 months predicts sustained DMARD-free remission
Filgotinib promising in RA patients naïve to methotrexate
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
Proteome abnormalities improve prediction of RA development
Biologics show similar activity in patients with elderly-onset RA
RA patients in remission benefit from continued therapy with conventional DMARDs
Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration
Treatment decisions should not be guided by ultrasound findings
Cancer treatment with checkpoint inhibitors in RA patients?
TNFi for RA during pregnancy – to stop or not to stop?
Cohort study shows improvement during 25 years of RA treatment
Filgotinib in RA patients with inadequate response or naïve to methotrexate
Clinical effectiveness of fenebrutinib in RA patients with methotrexate or TNFi failure
Short methotrexate stop is safe in patients with RA
Tofacitinib is safe according to real-world data analysis
Switching upadacitinib and adalimumab is beneficial in refractory RA
Tapering of prednisone in RA patients who achieved low disease activity or remission with tocilizumab
Efficacy and safety of E6011 in RA patients with inadequate response to methotrexate
Preliminary efficacy and safety data of RG6125 in RA patients with an inadequate response to TNF inhibitors
Integrated 10-year analysis confirms safety profile abatacept
Switching among multiple infliximab biosimilars does not cause immunogenicity
NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors
Switch to sarilumab from adalimumab is efficacious and safe
Switching to biosimilar bDMARDs is safe and efficacious
No significant differences when tapering TNF blockers versus csDMARDs
Biologic drug levels and infection risk, and clinical effectiveness of sarilumab
